Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 2/20 | 0.53 |
| ▸ | DRD2 | P14416 | 7/20 | 0.53 |
| ▸ | HTR2A | P28223 | 6/20 | 0.53 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.53 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.52 |
| ▸ | HTR1A | P08908 | 1/20 | 0.50 |
| ▸ | HTR7 | P34969 | 2/20 | 0.49 |
| ▸ | HTR6 | P50406 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7000199 | 0.95 | ACHE (0.57) | ACHEDRD2HTR2AMCHR1SLC6A4 | |
| SCHEMBL6998101 | 0.85 | ADRA1D (0.39) | DRD2HTR2AMCHR1HTR1A | |
| SCHEMBL6991441 | 0.79 | SIGMAR1 (0.44) | DRD2HTR7 | |
| SCHEMBL6997795 | 0.77 | KCNH2 (0.45) | HTR2A | |
| SCHEMBL9531712 | 0.76 | ADRA1D (0.62) | ACHEDRD2HTR2AMCHR1SLC6A4 | |
| SCHEMBL6996001 | 0.75 | HTR7 (0.49) | DRD2HTR2ASLC6A4HTR1AHTR7 | |
| SCHEMBL6996279 | 0.75 | HTR7 (0.45) | DRD2HTR2ASLC6A4HTR1AHTR7 | |
| SCHEMBL1545669 | 0.75 | ACHE (0.71) | ACHEDRD2HTR2AMCHR1SLC6A4 | |
| SCHEMBL8412376 | 0.74 | DRD2 (0.54) | ACHEDRD2HTR2ASLC6A4HTR1A | |
| SCHEMBL7351897 | 0.74 | ACHE (0.91) | ACHEDRD2HTR2ASLC6A4HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6664251-B2 | Serotonin receptor antagonist; treating cardiovascular disorder | DAIICHI SUNTORY PHARMA CO., LTD. (JP) | 2003-12-16 | — | — | US | disclosed |
| EP-0686632-B1 | BENZOTHIAZINE DERIVATIVE | DAIICHI SUNTORY PHARMA CO LTD (JP) | 2003-08-06 | — | — | EP | disclosed |
| US-20030078256-A1 | Benzothiazine derivative | SUNTORY LIMITED (JP) | 2003-04-24 | — | — | US | disclosed |
| US-6316442-B1 | TREATMENT OF HEART DISEASE AND CEREBROVASCULAR DISTURBANCES | SUNTORY LIMITED (JP) | 2001-11-13 | — | — | US | disclosed |
| US-6001827-A | Benzothiazine derivative | SUNTORY LIMITED (JP) | 1999-12-14 | — | — | US | disclosed |
| EP-0686632-A1 | BENZOTHIAZINE DERIVATIVE | SUNTORY LIMITED (JP) | 1995-12-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030078256-A1 | Benzothiazine derivative | TPH2, ADRB2, TPH1 | ACHE 3578/4885DRD2 402/4885HTR2A 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.